INOTEK PHARMACEUTICALS CORP's ticker is and the CUSIP is 45780VAB8. A total of 9 filers reported holding INOTEK PHARMACEUTICALS CORP in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $1,098,000 | +10.8% | 1,000,000 | 0.0% | 0.16% | -7.9% |
Q3 2019 | $991,000 | -65.8% | 1,000,000 | -64.3% | 0.18% | -57.9% |
Q2 2019 | $2,895,000 | +2.3% | 2,800,000 | 0.0% | 0.42% | +19.3% |
Q1 2019 | $2,830,000 | -62.1% | 2,800,000 | -63.6% | 0.35% | -70.1% |
Q4 2018 | $7,469,000 | -13.1% | 7,700,000 | 0.0% | 1.18% | +14.6% |
Q3 2018 | $8,592,000 | +9.1% | 7,700,000 | 0.0% | 1.03% | -4.5% |
Q2 2018 | $7,875,000 | +5.5% | 7,700,000 | 0.0% | 1.08% | -6.8% |
Q1 2018 | $7,466,000 | +23.7% | 7,700,000 | 0.0% | 1.16% | +26.2% |
Q4 2017 | $6,036,000 | -26.2% | 7,700,000 | -24.5% | 0.92% | -31.0% |
Q3 2017 | $8,180,000 | +26.8% | 10,200,000 | 0.0% | 1.33% | +38.2% |
Q2 2017 | $6,453,000 | -1.6% | 10,200,000 | 0.0% | 0.96% | -22.0% |
Q1 2017 | $6,557,000 | -35.6% | 10,200,000 | +5.2% | 1.23% | -39.2% |
Q4 2016 | $10,181,000 | +3.5% | 9,700,000 | +34.7% | 2.02% | +8.6% |
Q3 2016 | $9,839,000 | – | 7,200,000 | – | 1.86% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TFG Asset Management GP Ltd | 9,700,000 | $10,181,000 | 2.02% |
Telemetry Investments, L.L.C. | 1,000,000 | $1,040,000 | 0.59% |
DAFNA Capital Management LLC | 600,000 | $618,000 | 0.54% |
Bruce & Co., Inc. | 2,000,000 | $2,080,000 | 0.54% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 5,700,000 | $5,928,000 | 0.29% |
Orbimed Advisors | 7,000,000 | $7,354,000 | 0.09% |
Baker Brothers Advisors | 5,000,000 | $5,167,000 | 0.05% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 2,000,000 | $2,044,000,000 | 0.04% |
Citadel Advisors | 15,000,000 | $15,394,000 | 0.02% |
WOLVERINE ASSET MANAGEMENT LLC | 1,000,000 | $1,033,000 | 0.01% |